Corporate Presentation

1-7-21 Investor Update

January 7, 2021

GTB-3550 TriKE™ - Target Directed Serial Killing of AML Cancer Cell by NK Cells

January 7, 2021

GTB-3550 ASH 2020 Meeting Supplement Presentation – Treatment of HR-MDS Patient

December 16, 2020

GTB-3550 Clinical Trial Interim Results: Erica Warlick, M.D., Principal Investigator. American Society of Hematology (ASH) meeting, December 5, 2020.

December 5, 2020

GT Biopharma Interview with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco